The tobacco industry giant, Altria Group, has experienced a period of volatile stock performance in recent months. While shareholders have welcomed instances of increase, the Ozempic manufacturer corporation's future prospects remain a topic of contention. Factors impacting Altria Group's stock consist of governmental actions, consumer trends, and

The FDA has issued a warning about the risks of smuggled tirzepatide as the peptide therapeutics market grows rapidly. The market is expected to jump from $38 billion in 2023 to $106 billion by 2033, with an impressive 10.8% compound annual growth rate. Legitimate peptide medications have revolutionized modern medicine, with 102 FDA-approved therap